Medication info
Ritamezin Extended-release Tablet 5/1000 mg (Linagliptin (Unmodified), Metformin Hydrochloride)

Ritamezin Extended-release Tablet 5/1000 mg (Linagliptin (Unmodified), Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
White oval extended-release film-coated tablets
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202400184 · Approved 2024.01.24 · Insurance code 648104990

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication is prescribed to assist blood sugar control in patients with type 2 diabetes who use both linagliptin and metformin, complementing dietary and exercise therapy. It effectively lowers blood sugar levels, improving diabetes management and helping to enhance the overall health status of the patient.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This drug is a medication that helps control blood sugar and contains linagliptin and metformin hydrochloride as active ingredients. Caution should be taken as a rare side effect called lactic acidosis may occur when using this drug. Lactic acidosis is a dangerous condition caused by excessive accumulation of lactic acid in the body and may require immediate treatment. This drug should not be used in the following patients: those allergic to this drug or its components, type 1 diabetes patients, patients with severe renal dysfunction, those expected to experience acute renal function changes due to dehydration or severe infection, patients with severe hepatic dysfunction, acute alcohol intoxication patients, those in a very poor nutritional state, or those in specific high-risk situations during pregnancy. There is a risk of hypoglycemia; thus, blood sugar changes should be closely monitored, especially when used with insulin or sulfonylurea drugs. Additionally, excessive drinking or prolonged fasting should be avoided during metformin treatment. Kidney function significantly affects the efficacy and safety of this drug; regular kidney function tests should be performed before and during treatment. Caution is needed in the elderly with decreased kidney function, and dose adjustments may be required. Patients with poor cardiac function or conditions such as acute myocardial infarction or shock should also exercise caution when using this drug. Before and after examinations using iodinated contrast media, this drug should be temporarily discontinued and restarted only after kidney function has recovered. This drug should be swallowed whole and not chewed or crushed; however, the drug's coating may pass out in the stool, which is normal. Women who are pregnant or breastfeeding are advised to avoid using this drug, and if planning to become pregnant, consultation with a physician is necessary. If any symptoms such as abdominal pain, severe muscle pain, shortness of breath, skin rash, edema, persistent cough, or sudden weight gain occur during use, medical personnel should be informed immediately. This drug may interact with various medications; therefore, it is essential to inform your doctor or pharmacist if you are taking other medicines. Elderly patients or those with impaired kidney function should manage their condition through regular examinations and avoid exceeding the maximum dosage. In case of overdose, measures may be necessary to remove the drug from the gastrointestinal tract, and hemodialysis may be required to eliminate the drug if necessary. This drug should be stored out of reach of children and kept away from moisture and direct sunlight.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 120 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function
  • hepatitis
  • itching
  • erythema
  • rash
  • pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reaction
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • speech disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • runny nose
  • lung mass
  • joint pain
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • hypertension
  • goiter
  • erectile dysfunction
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • vitreous hemorrhage
  • stomatitis
  • mediastinitis
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture; therefore, it must be stored in a tightly closed container during use. Additionally, it should be kept away from extreme heat or cold, ideally stored at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White oval extended-release film-coated tablets

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.